SSRIs and SNRIs for Hot Flashes: Effective, but About Half as Powerful as Estrogen

For women who cannot take hormone therapy — including breast cancer survivors, those with clotting disorders, or women with a personal preference against hormonal treatment — selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) represent the most studied non-hormonal pharmacological option for vasomotor symptoms. This clinical review synthesizes evidence from multiple randomized controlled trials and finds that SSRIs and SNRIs reduce hot flash frequency and severity by 50 to 60 percent, compared to 80 to 90 percent for standard-dose estrogen. Paroxetine demonstrated the largest reductions — 62% at 12.5 mg/day and 64% at 25 mg/day — and remains the only SSRI with FDA approval specifically for vasomotor symptoms (marketed as Brisdelle). Among SNRIs, venlafaxine showed the strongest first-line evidence.

The evidence base spans a 2013 systematic review and meta-analysis of 11 randomized controlled trials including over 2,000 women aged 36 to 76, followed for one to nine months. Side effects — primarily nausea and constipation — tend to resolve within the first week. SNRIs require monitoring for blood pressure elevation. Importantly, these medications are not treating depression in this context; they are modulating the serotonergic pathways that interact with the thermoregulatory center. A woman does not need to be depressed to benefit from an SSRI for hot flashes, and the effective doses for vasomotor symptoms are often lower than those used for mood disorders.

Why This Matters

The existence of non-hormonal alternatives matters enormously for clinical equity — not every woman can safely use estrogen, and no woman should be left without options. But the 50 to 60 percent efficacy rate also means that SSRIs and SNRIs do not work equally well for everyone. Some women experience near-complete relief; others see marginal improvement. The only way to know which category a patient falls into is systematic tracking: baseline hot flash frequency and severity, then the same measurements after treatment initiation. This before-and-after comparison, captured in real tracking data rather than recalled in a quarterly office visit, is what turns a trial prescription into an informed treatment decision.